Moving from clinician-defined to patient-reported outcome measures for survivors of high-grade glioma

References

• Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–820. doi:10.1007/s00401-016-1545-127157931
   PubMed Web of Science ®Google Scholar
• Armstrong TS, Vera-Bolanos E, Acquaye AA, Gilbert MR, Ladha H, Mendoza T. The symptom burden of primary brain tumors: evidence for a core set of tumor- and treatment-related symptoms. Neuro-oncol. 2016;18(2):252–260. doi:10.1093/neuonc/nov16626289592
   PubMed Web of Science ®Google Scholar
• Brandel MG, Alattar AA, Hirshman BR, et al. Survival trends of oligodendroglial tumor patients and associated clinical practice patterns: a SEER-based analysis. J Neurooncol. 2017;133(1):173–181. doi:10.1007/s11060-017-2430-z28439777
   PubMed Web of Science ®Google Scholar
• Rusthoven CG, Carlson JA, Waxweiler TV, et al. The impact of adjuvant radiation therapy for high-grade gliomas by histology in the United States population. Int J Radiat Oncol Biol Phys. 2014;90(4):894–902. doi:10.1016/j.ijrobp.2014.07.04625585784
   PubMed Web of Science ®Google Scholar
• Smoll NR, Hamilton B. Incidence and relative survival of anaplastic astrocytomas. Neuro-oncol. 2014;16(10):1400–1407. doi:10.1093/neuonc/nou05324723565
   PubMed Web of Science ®Google Scholar
• Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–466. doi:10.1016/S1470-2045(09)70025-719269895
   PubMed Web of Science ®Google Scholar
• Weller M, van Den Bent M, Hopkins K, et al. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol. 2014;15(9):e395–e403. doi:10.1016/S1470-2045(14)70011-725079102
   PubMed Web of Science ®Google Scholar
• Dirven L, Aaronson NK, Heimans JJ, Taphoorn M. Health-related quality of life in high-grade glioma patients. Chin J Cancer. 2014;33:40–45. doi:10.5732/cjc.013.1021424384239
   PubMed Web of Science ®Google Scholar
• Dirven L, Armstrong TS, Blakeley JO, et al. Working plan for the use of patient-reported outcome measures in adults with brain tumours: a Response Assessment in Neuro-Oncology (RANO) initiative. Lancet Oncol. 2018;19(3):e173–e180. doi:10.1016/S1470-2045(18)30004-429508764
   PubMed Web of Science ®Google Scholar
• Arpinelli F, Bamfi F. The FDA guidance for industry on PROs: the point of view of a pharmaceutical company. Health Qual Life Outcomes. 2006;4(1):85. doi:10.1186/1477-7525-4-8517076891
   PubMed Web of Science ®Google Scholar
• Lovely MP, Stewart-Amidei C, Page M, et al. A new reality: long-term survivorship with a malignant brain tumor. Oncol Nurs Forum. 2013;40(3):267–274. doi:10.1188/13.ONF.267-27423615139
   PubMed Web of Science ®Google Scholar
• Molassiotis A, Wilson B, Brunton L, Chaudhary H, Gattamaneni R, McBain C. Symptom experience in patients with primary brain tumours: a longitudinal exploratory study. Eur J Oncol Nurs. 2010;14(5):410–416. doi:10.1016/j.ejon.2010.03.00120363189
   PubMed Web of Science ®Google Scholar
• Piil K, Juhler M, Jakobsen J, Jarden M. Daily life experiences of patients with a high-grade glioma and their caregivers: a longitudinal exploration of rehabilitation and supportive care needs. J Neurosci Nurs. 2015;47(5):271–284. doi:10.1097/JNN.000000000000015826348432
   PubMed Web of Science ®Google Scholar
• Sherwood P, Hricik A, Donovan H, et al. Changes in caregiver perceptions over time in response to providing care for a loved one with a primary malignant brain tumor. Oncol Nurs Forum. 2011;38(2):149–155. doi:10.1188/11.ONF.149-15521356653
   PubMed Web of Science ®Google Scholar
• Sterckx W, Coolbrandt A, Dierckx de Casterle B, et al. The impact of a high-grade glioma on everyday life: a systematic review from the patient’s and caregiver’s perspective. Eur J Oncol Nurs. 2013;17(1):107–117. doi:10.1016/j.ejon.2012.04.00622658206
   PubMed Web of Science ®Google Scholar
• Leeper H, Milbury K. Survivorship care planning and implementation in neuro-oncology. Neuro-oncol. 2018;20(suppl7):vii40–vii46. doi:10.1093/neuonc/noy11030412260
   PubMed Web of Science ®Google Scholar
• Westman B, Cornelius B. My cancer care plan as a web-solution. Stud Health Technol Inform. 2016;225:921–922.27332410
   PubMedGoogle Scholar
• Marzorati C, Riva S, Pravettoni G. Who is a cancer survivor? A systematic review of published definitions. J Cancer Educ. 2017;32(2):228–237. doi:10.1007/s13187-016-0997-226854084
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. NCI dictionary of cancer terms: symptom management. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/symptom-management. Accessed 703, 2019; 2019
   Google Scholar
• Amidei C. Symptom-based interventions to promote quality survivorship. Neuro-oncol. 2018;20(suppl7):vii27–vii39. doi:10.1093/neuonc/noy10029905840
   PubMed Web of Science ®Google Scholar
• Beitz J, Gnecco C, Justice R. Quality-of-life end points in cancer clinical trials: the U.S. Food and Drug Administration perspective. J Natl Cancer Inst Monogr. 1996;20:7–9.
   Google Scholar
• Saxena S, Orley J. Quality of life assessment: the world health organization perspective. Eur Psychiatry. 1997;12(Supplement 3):263s–266s. doi:10.1016/S0924-9338(97)89095-519698578
   PubMed Web of Science ®Google Scholar
• Blakeley JO, Coons SJ, Corboy JR, Kline Leidy N, Mendoza TR, Wefel JS. Clinical outcome assessment in malignant glioma trials: measuring signs, symptoms, and functional limitations. Neuro-oncol. 2016;18 Suppl 2(Suppl2):ii13–ii20. doi:10.1093/neuonc/nov29126989128
   PubMed Web of Science ®Google Scholar
• Dirven L, Reijneveld JC, Taphoorn MJB. Health-related quality of life or quantity of life: a difficult trade-off in primary brain tumors? Semin Oncol. 2014;41(4):541–552. doi:10.1053/j.seminoncol.2014.06.00225173146
   PubMed Web of Science ®Google Scholar
• Armstrong T, Mendoza T, Cohen M, Morrissey M, Gilbert M, Cleeland C. Reliability and validity of the M.D. Anderson symptom inventory (MDASI-BT) in the primary brain tumor patient population. Neuro-oncol. 2004;6(4):355–356.
   Web of Science ®Google Scholar
• Levin V, Phuphanich S, Alfred Yung WK, et al. Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation ★. J Neuro Oncol. 2006;78(3):295–302. doi:10.1007/s11060-005-9098-5
   Web of Science ®Google Scholar
• Reardon DA, Fink KL, Mikkelsen T, et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol. 2008;26(34):5610. doi:10.1200/JCO.2007.15.277718981465
   PubMed Web of Science ®Google Scholar
• Roa W, Brasher P, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol. 2004;22(9):1583–1588. doi:10.1200/JCO.2004.06.08215051755
   PubMed Web of Science ®Google Scholar
• Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol. 2010;28(7):1168. doi:10.1200/JCO.2009.23.259520124186
   PubMed Web of Science ®Google Scholar
• van Den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized european organisation for research and treatment of cancer phase III trial. J Clin Oncol. 2006;24(18):2715–2722. doi:10.1200/JCO.2005.04.607816782911
   PubMed Web of Science ®Google Scholar
• Grabenbauer GG, Gerber K-D, Ganslandt O, et al. Effects of concurrent topotecan and radiation on 6-month progression-free survival in the primary treatment of glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2009;75(1):164–169. doi:10.1016/j.ijrobp.2009.04.01519695435
   PubMed Web of Science ®Google Scholar
• Henriksson R, Malmström A, Bergström P, et al. High-grade astrocytoma treated concomitantly with estramustine and radiotherapy. J Neuro Oncol. 2006;78(3):321–326. doi:10.1007/s11060-005-9106-9
   Web of Science ®Google Scholar
• Keime-Guibert F, Chinot O, Taillandier L, et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med. 2007;356(15):1527–1535. doi:10.1056/NEJMoa06590117429084
   PubMed Web of Science ®Google Scholar
• Kocher M, Frommolt P, Borberg SK, et al. Randomized study of postoperative radiotherapy and simultaneous temozolomide without adjuvant chemotherapy for glioblastoma. Strahlenther Onkol. 2008;184(11):572–579. doi:10.1007/s00066-008-1897-019016015
   PubMed Web of Science ®Google Scholar
• Malmström A, Grønberg BH, Marosi C, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the nordic randomised, phase 3 trial. Lancet Oncol. 2012;13(9):916–926. doi:10.1016/S1470-2045(12)70265-622877848
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van Den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996. doi:10.1056/NEJMoa04333015758009
   PubMed Web of Science ®Google Scholar
• Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012;48(14):2192–2202. doi:10.1016/j.ejca.2012.04.01122608262
   PubMed Web of Science ®Google Scholar
• Wick W, Platten M, Meisner C, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012;13(7):707–715. doi:10.1016/S1470-2045(12)70164-X22578793
   PubMed Web of Science ®Google Scholar
• Dirven L, Taphoorn MJB, Reijneveld JC, et al. The level of patient-reported outcome reporting in randomised controlled trials of brain tumour patients: a systematic review. Eur J Cancer. 2014;50(14):2432–2448. doi:10.1016/j.ejca.2014.06.01625034656
   PubMed Web of Science ®Google Scholar
• Brundage M, Blazeby J, Revicki D, et al. Patient-reported outcomes in randomized clinical trials: development of ISOQOL reporting standards. Qual Life Res. 2013;22(6):1161–1175. doi:10.1007/s11136-012-0252-122987144
   PubMed Web of Science ®Google Scholar
• Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814–822. doi:10.1001/jama.2013.87923443445
   PubMed Web of Science ®Google Scholar
• Taphoorn MJB, Dirven L, Kanner AA, et al. Influence of treatment with tumor-treating fields on health-related quality of life of patients with newly diagnosed glioblastoma: a secondary analysis of a randomized clinical trialtreatment with tumor-treating fields in patients with glioblastomatreatment with tumor-treating fields in patients with glioblastoma. JAMA Oncol. 2018;4(4):495–504. doi:10.1001/jamaoncol.2017.508229392280
   PubMed Web of Science ®Google Scholar
• Dirven LJ, van Den Bent M, Bottomley A, et al. The Impact of Bevacizumab on Health-related Quality of Life in Patients Treated for Recurrent Glioblastoma: Results of the Randomised Controlled Phase 2 BELOB Trial. Eur J Cancer 2015;51(10):1321-30.
   Google Scholar
• Dirven L, Reijneveld J, Aaronson N, Bottomley A, Uitdehaag B, Taphoorn M. Health-related quality of life in patients with brain tumors: limitations and additional outcome measures. Curr Neurol Neurosci Rep. 2013;13(7):1–9. doi:10.1007/s11910-013-0359-y
   Web of Science ®Google Scholar
• Dirven L, Armstrong TS, Taphoorn MJB. Health-related quality of life and other clinical outcome assessments in brain tumor patients: challenges in the design, conduct and interpretation of clinical trials. Neuro Oncol Pract. 2015;2(1):2–5. doi:10.1093/nop/npv002
   Google Scholar
• Roydhouse JK, Wilson IB. Systematic review of caregiver responses for patient health-related quality of life in adult cancer care. Qual Life Res. 2017;26(8):1925–1954. doi:10.1007/s11136-017-1540-628293821
   PubMed Web of Science ®Google Scholar
• Giesinger JM, Golser M, Erharter A, et al. Do neurooncological patients and their significant others agree on quality of life ratings? Health Qual Life Outcomes. 2009;7:87. doi:10.1186/1477-7525-7-8719814834
   PubMed Web of Science ®Google Scholar
• Sneeuw KC, Aaronson NK, Osoba D, et al. The use of significant others as proxy raters of the quality of life of patients with brain cancer. Med Care. 1997;35(5):490–506.9140337
   PubMed Web of Science ®Google Scholar
• Brown DP, Decker AP, Rummans AT, et al. A prospective study of quality of life in adults with newly diagnosed high-grade gliomas: comparison of patient and caregiver ratings of quality of life. Am J Clin Oncol. 2008;31(2):163–168. doi:10.1097/COC.0b013e318149f1d318391601
   PubMed Web of Science ®Google Scholar
• Jacobs DI, Kumthekar P, Stell BV, et al. Concordance of patient and caregiver reports in evaluating quality of life in patients with malignant gliomas and an assessment of caregiver burden. Neuro Oncol Pract. 2014;1(2):47–54. doi:10.1093/nop/npu004
   Google Scholar
• Stell B, Jacobs D, Grimm SA, et al. Quality-of-life concordance between patients with malignant gliomas and their caregivers: updated data. J Clin Oncol. 2011;29(15):9053. doi:10.1200/jco.2011.29.15_suppl.9053
   Web of Science ®Google Scholar
• Armstrong TS, Wefel JS, Gning I, et al. Congruence of primary brain tumor patient and caregiver symptom report. Cancer (0008543X). 2012;118(20):5026. doi:10.1002/cncr.27483
   PubMed Web of Science ®Google Scholar
• Gning I, Armstrong T, Wefel J, et al. ASSESSING THE VALIDITY OF THE MD ANDERSON SYMPTOM INVENTORY-BRAIN TUMOR (MDASI-BT) USING CAREGIVER PROXY REPORT. Neuro-oncol. 2012;14(s6):158.
   Google Scholar
• Fox P, Furlong E, Buick A, et al. The eSMART Project: Real-time Symptom Management in the Irish Oncology Setting. Cancer Professional, Summer, 2016:22-24.
   Google Scholar
• Snyder FC, Jensen ER, Segal BJ, Wu WA. Patient-reported outcomes (PROs): putting the patient perspective in patient-centered outcomes research. Med Care. 2013;51 Suppl(8 Suppl 3), Electronic Data Methods (EDM) Forum Special Supplement(8 Suppl 3):S73–S79. doi:10.1097/MLR.0b013e31829b1d8423774513
   PubMed Web of Science ®Google Scholar
• Basch E, Deal AM, Kris MG, et al. Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J Clin Oncol. 2015;34(6):557–565. doi:10.1200/JCO.2015.63.083026644527
   PubMed Web of Science ®Google Scholar
• Denis F, Lethrosne C, Pourel N, et al. Randomized trial comparing a web-mediated follow-up with routine surveillance in lung cancer patients. J Natl Cancer Inst. 2017;109(9):djx029. doi:10.1093/jnci/djx029
   Google Scholar
• Basch E, Abernethy AP. Supporting clinical practice decisions with real-time patient-reported outcomes. J Clin Oncol. 2011;29(8):954–956. doi:10.1200/JCO.2010.33.266821282536
   PubMed Web of Science ®Google Scholar
• Basch E, Spertus J, Adams Dudley R, et al. Methods for developing patient-reported outcome-based performance measures (PRO-PMs). Value Health. 2015;18(4):493–504. doi:10.1016/j.jval.2015.02.01826091604
   PubMed Web of Science ®Google Scholar
• Blackford AL, Wu AW, Snyder C. Interpreting and acting on PRO results in clinical practice: lessons learned from the patientviewpoint system and beyond. Med Care. 2019;57 Suppl 5(Suppl 1):S46–S51. doi:10.1097/MLR.000000000000108630985596
   PubMed Web of Science ®Google Scholar
• Loth F, Holzner B, Sztankay M, et al. Cancer patients’ understanding of longitudinal EORTC QLQ-C30 scores presented as bar charts. Patient Educ Couns. 2016;99(12):2012–2017. doi:10.1016/j.pec.2016.08.00427506581
   PubMed Web of Science ®Google Scholar
• Bantug ET, Coles T, Smith KC, Snyder CF, Rouette J, Brundage MD. Graphical displays of patient-reported outcomes (PRO) for use in clinical practice: what makes a pro picture worth a thousand words? Patient Educ Couns. 2016;99(4):483–490. doi:10.1016/j.pec.2015.10.02726603445
   PubMed Web of Science ®Google Scholar
• Snyder CF, Blackford AL, Okuyama T, et al. Using the EORTC-QLQ-C30 in clinical practice for patient management: identifying scores requiring a clinician’s attention. Qual Life Res. 2013;22(10):2685. doi:10.1007/s11136-012-0169-823532341
   PubMed Web of Science ®Google Scholar
• Snyder CF, Blackford AL, Sussman J, et al. Identifying changes in scores on the EORTC-QLQ-C30 representing a change in patients’ supportive care needs. Qual Life Res. 2015;24(5):1207–1216. doi:10.1007/s11136-014-0853-y25398495
   PubMed Web of Science ®Google Scholar
• Wintner LM, Sztankay M, Aaronson N, et al. The use of EORTC measures in daily clinical practice-A synopsis of a newly developed manual. Eur J Cancer. 2016;68:73–81. doi:10.1016/j.ejca.2016.08.02427721057
   PubMed Web of Science ®Google Scholar
• King S, Exley J, Parks S, et al. The use and impact of quality of life assessment tools in clinical care settings for cancer patients, with a particular emphasis on brain cancer: insights from a systematic review and stakeholder consultations. Qual Life Res. 2016;25(9):2245–2256. doi:10.1007/s11136-016-1278-627039304
   PubMed Web of Science ®Google Scholar
• Armstrong TS, Mendoza T, Gning I, et al. Validation of the M.D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT). J Neuro Oncol. 2006;80(1):27–35. doi:10.1007/s11060-006-9135-z
   Web of Science ®Google Scholar
• Armstrong TS, Cohen MZ, Eriksen LR, Hickey JV. Symptom clusters in oncology patients and implications for symptom research in people with primary brain tumors. J Nurs Scholarsh. 2004;36(3):197–206.15495487
   PubMed Web of Science ®Google Scholar
• Armstrong TS, Cron SG, Bolanos EV, Gilbert MR, Kang DH. Risk factors for fatigue severity in primary brain tumor patients. Cancer. 2010;116(11):2707–2715. doi:10.1002/cncr.2501820235192
   PubMed Web of Science ®Google Scholar
• Armstrong TS, Vera‐Bolanos E, Gning I, et al. The impact of symptom interference using the MD Anderson Symptom Inventory‐Brain Tumor Module (MDASI‐BT) on prediction of recurrence in primary brain tumor patients. Cancer. 2011;117(14):3222–3228. doi:10.1002/cncr.2589221264841
   PubMed Web of Science ®Google Scholar
• Lai JS, Jensen SE, Beaumont JL, et al. Development of a symptom index for patients with primary brain tumors. Value Health. 2014;17(1):62–69. doi:10.1016/j.jval.2013.11.00624438718
   PubMed Web of Science ®Google Scholar
• Rooney A, Netten A, McNamara S, et al. Assessment of a brain-tumour-specific patient concerns inventory in the neuro-oncology clinic. Support Care Cancer. 2014;22(4):1059–1069. doi:10.1007/s00520-013-2058-224292015
   PubMed Web of Science ®Google Scholar
• Young J, Cund A, Renshaw M, Quigley A, Snowden A. Improving the Care of Cancer Patients: Holistic Needs Assessment. Br J Nurs. 2015;24(4):S17-20. doi:10.12968/bjon.2015.24.Sup4.S17
   Google Scholar
• Liu F, Huang J, Zhang L, et al. Screening for distress in patients with primary brain tumor using distress thermometer: a systematic review and meta-analysis. BMC Cancer. 2018;18(1):124. doi:10.1186/s12885-018-4242-829394923
   PubMed Web of Science ®Google Scholar
• Trad W, Koh E-S, Daher M, et al. Screening for Psychological Distress in Adult Primary Brain Tumor Patients and Caregivers: Considerations for Cancer Care Coordination. Front Oncol. 2015;5:203. doi:10.3389/fonc.2015.00203
   Google Scholar
• Armstrong TS, Cohen MZ, Eriksen L, Cleeland C. Content validity of self-report measurement instruments: an illustration from the development of the brain tumor module of the M.D. Anderson symptom inventory. Oncol Nurs Forum. 2005;32(3):669–676. doi:10.1188/05.ONF.669-67615897941
   PubMed Web of Science ®Google Scholar
• Afseth J, Neubeck L, Karatzias T, Grant R. Holistic needs assessment in brain cancer patients: a systematic review of available tools. Neuro-oncol 2018;20(suppl1):i12–i12. doi:10.1093/neuonc/nox238.051
   Google Scholar
• Chang JH, Kim C-Y, Choi BS, Kim YJ, Kim JS, Kim IA. Pseudoprogression and pseudoresponse in the management of high-grade glioma: optimal decision timing according to the response assessment of the neuro-oncology working group. J Korean Neurosurg Soc. 2014;55(1):5–11. doi:10.3340/jkns.2014.55.1.524570811
   PubMed Web of Science ®Google Scholar
• Armstrong T, Gilbert M. Patient reported endpoints for measuring clinical benefit in (High grade glioma) primary brain tumor patients. Curr Treat Options Oncol. 2014;15(4):519–528. doi:10.1007/s11864-014-0302-825173554
   PubMed Web of Science ®Google Scholar
• Wen PY, Chang SM, Van Den Bent MJ, Vogelbaum MA, Macdonald DR, Lee EQ. Response assessment in neuro-oncology clinical trials. J Clin Oncol. 2017;35(21):2439. doi:10.1200/JCO.2017.72.751128640707
   PubMed Web of Science ®Google Scholar
• Armstrong TS, Wefel JS, Wang M, et al. Clinical utility of neurocognitive function (NCF), quality of life (QOL), and symptom assessment as prognostic factors for survival and measures of treatment effects on RTOG 0525. J Clin Oncol. 2011;29(15_suppl):2016. doi:10.1200/jco.2011.29.15_suppl.2016
   Web of Science ®Google Scholar
• Nayak L, DeAngelis LM, Brandes AA, et al. The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria. Neuro-oncol 2017;19(5):625–635. doi:10.1093/neuonc/nox02928453751
   PubMed Web of Science ®Google Scholar
• Oort Q, Dirven L, Meijer W, et al. Development of a questionnaire measuring instrumental activities of daily living (IADL) in patients with brain tumors: a pilot study. J Neuro Oncol. 2017;132(1):145–153. doi:10.1007/s11060-016-2352-1
   Web of Science ®Google Scholar
• Oort Q, Taphoorn MJB, Sikkes SAM, Uitdehaag BMJ, Reijneveld JC, Dirven L. Evaluation of the content coverage of questionnaires containing basic and instrumental activities of daily living (ADL) used in adult patients with brain tumors. J Neuro Oncol. 2019;143(1):1–13. doi:10.1007/s11060-019-03136-9
   PubMed Web of Science ®Google Scholar
• van Leeuwen M, Husson O, Alberti P, et al. Understanding the quality of life (QOL) issues in survivors of cancer: towards the development of an EORTC QOL cancer survivorship questionnaire. Health Qual Life Outcomes. 2018;16(1):114. doi:10.1186/s12955-018-0920-0
   Google Scholar
• Petersen MA, Aaronson NK, Arraras JI, et al. The EORTC CAT Core-The computer adaptive version of the EORTC QLQ-C30 questionnaire. Eur J Cancer. 2018;100:8–16. doi:10.1016/j.ejca.2018.04.01629936066
   PubMed Web of Science ®Google Scholar
• Wagner LI, Schink J, Bass M, et al. Bringing PROMIS to practice: brief and precise symptom screening in ambulatory cancer care. Cancer. 2015;121(6):927–934. doi:10.1002/cncr.2910425376427
   PubMed Web of Science ®Google Scholar
• Gabel N, Altshuler DB, Brezzell A, et al. Health related quality of life in adult low and high-grade glioma patients using the national institutes of health Patient Reported Outcomes Measurement Information System (PROMIS) and Neuro-QOL Assessments. Front Neurol. 2019;10:212. doi:10.3389/fneur.2019.0021230930834
   PubMed Web of Science ®Google Scholar
• Drewes C, Sagberg LM, Jakola AS, Gulati S, Solheim O. Morbidity after intracranial tumor surgery: sensitivity and specificity of retrospective review of medical records compared with patient-reported outcomes at 30 days. J Neurosurg. 2015;123(4):972–977. doi:10.3171/2014.12.JNS14220626252464
   PubMed Web of Science ®Google Scholar
• Ediebah DE, Reijneveld JC, Taphoorn MJB, et al. Impact of neurocognitive deficits on patient–proxy agreement regarding health-related quality of life in low-grade glioma patients. Qual Life Res. 2017;26(4):869–880. doi:10.1007/s11136-016-1426-z27744512
   PubMed Web of Science ®Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–376. doi:10.1093/jnci/85.5.3658433390
   PubMed Web of Science ®Google Scholar
• Taphoorn MJ, Claassens L, Aaronson NK, et al. An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients. Eur J Cancer. 2010;46(6):1033–1040. doi:10.1016/j.ejca.2010.01.01220181476
   PubMed Web of Science ®Google Scholar
• Cella DF, Tulsky DS, Gray G, et al. The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11(3):570. doi:10.1200/JCO.1993.11.12.24118445433
   PubMed Web of Science ®Google Scholar
• Osoba D, Aaronson NK, Muller M, et al. The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. Qual Life Res. 1996;5(1):139–150.8901377
   PubMed Web of Science ®Google Scholar
• Weitzner M, Meyers C, Gelke C, Byrne K, Cella D, Levin V. The Functional Assessment of Cancer Therapy (FACT) Scale - Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer. 1995;75(5):1151–1161. doi:10.1002/1097-0142(19950301)75:5<1151::aid-cncr2820750515>3.0.co;2-q7850714
   PubMed Web of Science ®Google Scholar
• Armstrong TS. Development and Validation of the Neuro Symptom Inventory in the Primary Brain Tumor Patient Population. Texas Medical Center Dissertations (via ProQuest). AAI3198902. University of Texas School of Nursing at Houston; 2005.
   Google Scholar
• Bonevski B, Sanson-Fisher R, Girgis A, Burton L, Cook P, Boyes A. Evaluation of an instrument to assess the needs of patients with cancer. (Supportive Care Review Group). Cancer. 2000;88(1):217. doi:10.1002/(SICI)1097-0142(20000101)88:1<217::AID-CNCR29>3.0.CO;2-Y10618626
   PubMed Web of Science ®Google Scholar
• Janda M, Steginga S, Dunn J, Langbecker D, Walker D, Eakin E. Unmet supportive care needs and interest in services among patients with a brain tumour and their carers. Patient Educ Couns. 2008;71(2):251–258. doi:10.1016/j.pec.2008.01.02018329220
   PubMed Web of Science ®Google Scholar